Immix Biopharma Announces Class-Leading Safety Profile, Allowing Potential Future Indication Expansion
Provided By GlobeNewswire
Last update: Jul 11, 2025
– Absence of neurotoxicity of any grade in low-volume disease to-date –
– On track for first Biologics License Application (BLA) approved cell therapy in orphan indication relapsed/refractory AL Amyloidosis –
Read more at globenewswire.com
